Monoamine oxidase as a target for drug action;Oksydaza monoaminowa jako miejsce działania leków

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 60, Issue , 2006, Pages 498-515

  Drozak, Jakub ^a   Kozłowski, Marcin ^a  

^a UNIVERSITY OF WARSAW   (Poland)

Author keywords

Depression; Monoamine oxidase; Monoamine oxidase inhibitors; Neurodegenerative diseases

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; MONOAMINE OXIDASE INHIBITOR; TYRAMINE;

ALZHEIMER DISEASE; ANIMAL; DEPRESSION; HUMAN; METABOLISM; PARKINSON DISEASE; REVIEW;

ALZHEIMER DISEASE; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; DEPRESSION; HUMANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; TYRAMINE;

EID: 39049181653     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: None     Document Type: Review

References (147)

1. Abell C.W., Kwan S.W.: Molecular characterization of monoamine oxidases A and B. Prog. Nucleic Acid Res. Mol. Biol., 2001; 65: 129-156
2. Adeghate E., Parvez H.: The effect of diabetes mellitus on the morphology and physiology of monoamine oxidase in the pancreas. Neurotoxicology, 2004; 25: 167-173
3. Akhondzadeh S., Tavakolian R., Davari-Ashtiani R., Arabgol F., Amini H.: Selegiline in the treatment of attention deficit hyperactivity disorder in children: A double blind and randomized trial. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003; 27: 841-845
4. Am O.B., Amit T., Youdim M.B.: Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett., 2004; 355: 169-172
5. Anttila M., Sotaniemi E.A., Pelkonen O., Rautio A.: Marked effect of liver and kidney function on the pharmacokinetics of selegiline. Clin. Pharmacol. Ther., 2005; 77: 54-62
6. Baker G.B., Urichuk L.J., McKenna K.F., Kennedy S.H.: Metabolism of monoamine oxidase inhibitors. Cell. Mol. Neurobiol., 1999; 19: 411-426
7. Barsky J., Pacha W.L., Sarkar S., Zeller E.A.: Amine oxidases. XVII. Mode of action of 1-isonicotinyl-2-isopropylhydrazine on monoamine oxidase. J. Biol. Chem., 1959; 234: 389-391
8. Bertorello A.M, Sznajder J.I.: The dopamine paradox in lung and kidney epithelia: sharing the same target but operating different signaling networks. Am. J. Respir. Cell Mol. Biol., 2005; 33: 432-437
9. Bieck P.R., Firkusny L., Schick C., Antonin K.H., Nilsson E., Schulz R., Schwenk M., Wollmann H.: Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. Clin. Pharmacol. Ther., 1989; 45: 260-269
10. Billett E.E.: Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicology, 2004; 25: 139-148
11. Billett E.E., Mayer R.J.: Monoclonal antibodies to monoamine oxidase B and another mitochondrial protein from human liver. Biochem. J., 1986; 235: 257-263
12. Birkmayer W., Knoll J., Riederer P., Youdim M.B., Hars V., Marton J.: Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: A longterm study. J. Neural. Transm., 1985; 64: 113-127
13. Birkmayer W., Riederer P., Youdim M.B., Linauer W.: The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J. Neural. Transm., 1975; 36: 303-326
14. Bloch R.G., Dooneief A.S., Buchberg A.S., Spellman S.: The clinical effect of isoniazid and iproniazid in the treatment of pulmonary tuberculosis. Ann. Intern. Med., 1954; 40: 881-900
15. Bodkin J.A., Amsterdam J.D.: Transdermal selegiline in major depression: A double-blind, placebo-controlled, parallel-group study in outpatients. Am. J. Psychiatry., 2002; 159: 1869-1875
16. Bonuccelli U., Piccini P., Del Dotto P., Pacifici G.M., Corsini G.U., Muratorio A. Platelet monoamine oxidase B activity in parkinsonian patients. J. Neurol. Neurosurg. Psychiatry, 1990; 53: 854-855
17. Brunner H.G., Nelen M., Breakefield X.O., Ropers H.H., van Oost B.A.: Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science, 1993; 262: 578-580
18. Buckman T.D., Eiduson S., Sutphin M.S., Chang R.: Selective effects on catalysis by the multiple forms of monoamine oxidase produced by interactions of acidic phospholipids with mitochondrial membranes. J. Biol. Chem., 1983; 258: 8670-8676
19. Carlile G.W., Chalmers-Redman R.M., Tatton N.A., Pong A., Borden K.E., Tatton W.G.: Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol. Pharmacol., 2000; 57: 2-12
20. Carrasco G., Cruz M.A., Dominguez A., Gallardo V., Miguel P., Gonzalez C.: The expression and activity of monoamine oxidase A, but not of the serotonin transporter, is decreased in human placenta from pre-eclamptic pregnancies. Life Sci., 2000; 67: 2961-2969
21. Carrasco G., Cruz M.A., Gallardo V., Miguel P., Lagos M., Gonzalez C.: Plasma and platelet concentration and platelet uptake of serotonin in normal and pre-eclamptic pregnancies. Life Sci., 1998; 62: 1323-1332
22. Cases O., Seif I., Grimsby J., Gaspar P., Chen K., Pournin S., Muller U., Aguet M., Babinet C., Shih J.C.: Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science, 1995; 268: 1763-1766
23. Castagnoli K., Murugesan T.: Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links? Neurotoxicology, 2004; 25: 279-291
24. Chen Z.Y., Hotamisligil G.S., Huang J.K., Wen L., Ezzeddine D., Aydin-Muderrisoglu N., Powell J.F., Huang R.H., Breakefield X.O., Craig I.: Structure of the human gene for monoamine oxidase type A. Nucleic. Acids Res., 1991; 19: 4537-4541
25. Chen Z.Y., Powell J.F., Hsu Y.P., Breakefield X.O., Craig I.W.: Organization of the human monoamine oxidase genes and long-range physical mapping around them. Genomics, 1992; 14: 75-82
26. Chiou S.H., Ku H.H., Tsai T.H., Lin H.L., Chen L.H., Chien C.S., Ho L.L., Lee C.H., Chang Y.L.: Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway. Br. J. Pharmacol., 2006; 148: 587-598
27. Christen Y.: Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr., 2000; 71: 621S-629S
28. Denney R.M., Fritz R.R., Patel N.T., Widen S.G., Abell C.W.: Use of a monoclonal antibody for comparative studies of monoamine oxidase B in mitochondrial extracts of human brain and peripheral tissues. Mol. Pharmacol., 1983; 24: 60-68
29. Denney R.M., Patel N.T., Fritz R.R., Abell C.W.: A monoclonal antibody elicited to human platelet monoamine oxidase. Isolation and specificity for human monoamine oxidase B but not A. Mol. Pharmacol., 1982; 22: 500-508
30. Derry J.M., Lan N.C., Shih J.C., Barnard E.A., Barnard P.J.: Localization of monoamine oxidase A and B genes on the mouse X chromosome. Nucleic. Acids Res., 1989; 17: 8403
31. Duman R.S.: Neurotrophic factors and regulation of mood: role of exercise, diet and metabolism. Neurobiol. Aging, 2005; 26(Suppl.1): 88-93
32. Duman R.S.: Depression: A case of neuronal life and death? Biol. Psychiatry, 2004; 56: 140-145
33. Ebadi M., Sharma S., Shavali S., El Refaey H.: Neuroprotective actions of selegiline. J. Neurosci. Res. 2002; 67: 285-289
34. Edmondson D.E., Mattevi A., Binda C., Li M., Hubalek F.: Structure and mechanism of monoamine oxidase. Curr. Med. Chem., 2004; 11: 1983-1993
35. Egan C.G.: Differentiation of hippocampal stem cells into functional neurons: evolving our understanding of monoamine oxidase-A inhibition. Br. J. Pharmacol., 2006; 148: 563-564
36. Finberg J.P., Tenne M.: Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br. J. Pharmacol., 1982; 77: 13-21
37. Fischer P., Gotz M.E., Ellinger B., Streifler M., Riederer P., Danielczyk W.: Platelet monoamine oxidase B activity and Vitamin B12 in dementia. Biol. Psychiatry, 1994; 35: 772-774
38. Foley P., Gerlach M., Youdim M.B., Riederer P.: MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Rel. Disord., 2000; 6: 25-47
39. Fowler J.S., Logan J., Wang G.J., Volkow N.D., Telang F., Ding Y.S., Shea C., Garza V., Xu Y., Li Z., Alexoff D., Vaska P., Ferrieri R., Schlyer D., Zhu W., John Gatley S.: Comparison of the binding of the irreversible monoamine oxidase tracers [(11)C]clorgyline and[(11)C]ldeprenyl in brain and peripheral organs in humans. Nucl. Med. Biol., 2004; 31: 313-319
40. Fowler J.S., Logan J., Wang G.J., Volkow N.D., Zhu W., Franceschi D., Pappas N., Ferrieri R., Shea C., Garza V., Xu Y., MacGregor R.R., Schlyer D., Gatley S.J., Ding Y.S., Alexoff D.: PET imaging of monoamine oxidase B in peripheral organs in humans. J. Nucl. Med., 2002; 43: 1331-1338
41. Fowler J.S., MacGregor R.R., Wolf A.P., Arnett C.D., Dewey S.L., Schlyer D., Christman D., Logan J., Smith M., Sachs H.: Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Science, 1987; 235: 481-485
42. Fowler C.J., Magnusson O., Ross S.B.: Intra-and extraneuronal monoamine oxidase. Blood Vessels, 1984; 21: 126-131
43. Fowler C.J., Ross S.B.: Selective inhibitors of monoamine oxidase A and B: biochemical, pharmacological, and clinical properties. Med. Res. Rev., 1984; 4: 323-358
44. Gasteiger E., Gattiker A., Hoogland C., Ivanyi I., Appel R.D., Bairoch A.: ExPASy: The proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res., 2003; 31: 3784-3788
45. Geha R.M., Chen K., Wouters J., Ooms F., Shih J.C.: Analysis of conserved active site residues in monoamine oxidase A and B and their three-dimensional molecular modeling. J. Biol. Chem., 2002; 277: 17209-17216
46. Geha R.M., Rebrin I., Chen K., Shih J.C.: Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid. J. Biol. Chem., 2001; 276: 9877-9882
47. Glover V., Sandler M.: Clinical chemistry of monoamine oxidase. Cell. Biochem. Funct., 1986; 4: 89-97
48. Goldman L.S., Nielsen N.H., Champion H.C.: Awareness, diagnosis, and treatment of depression. J. Gen. Intern. Med., 1999; 14: 569-580
49. Gotz M.E., Fischer P., Gsell W., Riederer P., Streifler M., Simanyi M., Muller F., Danielczyk W.: Platelet monoamine oxidase B activity in dementia. A 4-year follow-up. Dement. Geriatr. Cogn. Disord., 1998; 9: 74-77
50. Grimsby J., Chen K., Wang L.J., Lan N.C., Shih J.C.: Human monoamine oxidase A and B genes exhibit identical exon-intron organization. Proc. Natl. Acad. Sci. USA, 1991; 88: 3637-3641
51. Grimsby J., Toth M., Chen K., Kumazawa T., Klaidman L., Adams J.D., Karoum F., Gal J., Shih J.C.: Increased stress response and betaphenylethylamine in MAOB-deficient mice. Nat. Genet., 1997; 17: 206-210
52. Gutteridge J.M., Halliwell B.: Free radicals and antioxidants in the year 2000. A historical look to the future. Ann. NY Acad. Sci., 2000; 899: 136-147
53. Hara M.R., Thomas B., Cascio M.B., Bae B.I., Hester L.D., Dawson V.L., Dawson T.M., Sawa A., Snyder S.H.: Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc. Natl. Acad. Sci. USA, 2006; 103: 3887-3889
54. Hare M.L.: Tyramine oxidase. I. A new enzyme system in liver. Biochem. J., 1928; 22: 968-979
55. Hashimoto S., Inoue T., Koyama T.: Effects of conditioned fear stress on serotonin neurotransmission and freezing behavior in rats. Eur. J. Pharmacol., 1999; 378: 23-30
56. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C.: Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature, 1984; 311: 467-469
57. Heimberg R.G., Liebowitz M.R., Hope D.A., Schneier F.R., Holt C.S., Welkowitz L.A., Juster H.R., Campeas R., Bruch M.A., Cloitre M., Fallon B., Klein D.F.: Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch. Gen. Psychiatry, 1998; 55: 1133-1141
58. Hiro I., Tsugeno Y., Hirashiki I., Ogata F., Ito A.: Characterization of rat monoamine oxidase A with noncovalently-bound FAD expressed in yeast cells. J. Biochem., 1996; 120: 759-765
59. Holschneider D.P., Scremin O.U., Chialvo D.R., Chen K., Shih J.C.: Heart rate dynamics in monoamine oxidase-A-and-B-deficient mice. Am. J. Physiol. Heart Circ. Physiol., 2002; 282: H1751-H1759
60. Holschneider D.P., Scremin O.U., Roos K.P., Chialvo D.R., Chen K., Shih J.C.: Increased baroreceptor response in mice deficient in monoamine oxidase A and B. Am. J. Physiol. Heart Circ. Physiol., 2002; 282: H964-H972
61. Holt A., Berry M.D., Boulton A.A.: On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited. Neurotoxicology, 2004; 25: 251-266
62. Hussain T., Lokhandwala M.F.: Renal dopamine receptors and hypertension. Exp. Biol. Med., 2003; 228: 134-142
63. Jenei V., Zor K., Magyar K., Jakus J.: Increased cell-cell adhesion, a novel effect of R-(-)-deprenyl. J. Neural. Transm., 2005; 112: 1433-1445
64. Katagi M., Tatsuno M., Miki A., Nishikawa M., Nakajima K., Tsuchihashi H.: Simultaneous determination of selegiline-N-oxide, a new indicator for selegiline administration, and other metabolites in urine by high-performance liquid chromatography-electrospray ionization mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl., 2001; 759: 125-133
65. Kennedy S.H.: Continuation and maintenance treatments in major depression: The neglected role of monoamine oxidase inhibitors. J. Psychiatry Neurosci., 1997; 22: 127-131
66. Khalil A.A., Davies B., Castagnoli N.: Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke. Bioorg. Med. Chem., 2006; 14: 3392-3398
67. Kiray M., Bagriyanik H.A., Pekcetin C., Ergur B.U., Uysal N., Ozyurt D., Buldan Z.: Deprenyl and the relationship between its effects on spatial memory, oxidant stress and hippocampal neurons in aged male rats. Physiol. Res., 2006; 55: 205-212
68. Kochersperger L.M., Parker E.L., Siciliano M., Darlington G.J., Denney R.M.: Assignment of genes for human monoamine oxidases A and B to the X chromosome. J. Neurosci. Res., 1986; 16: 601-616
69. Langston J.W., Ballard P., Tetrud J.W., Irwin I.: Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 1983; 219: 979-980
70. Lenders J.W., Eisenhofer G., Abeling N.G., Berger W., Murphy D.L., Konings C.H., Wagemakers L.M., Kopin I.J., Karoum F., van Gennip A.H., Brunner H.G.: Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. J. Clin. Invest., 1996; 97: 1010-1019
71. Lewinsohn R., Glover V., Sandler M.: b-Phenylethylamine and benzylamine as substrates for human monoamine oxidase A: A source of some anomalies? Biochem. Pharmacol., 1980; 29: 777-781
72. Lewinsohn R., Glover V., Sandler M.: Development of benzylamine oxidase and monoamine oxidase A and B in man. Biochem. Pharmacol., 1980; 29: 1221-1230
73. Loomer H.P., Saunders J.C., Kline N.S.: A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr. Res. Rep. Am. Psychiatr. Assoc., 1957; 135: 129-141
74. Ma J., Ito A.: Tyrosine residues near the FAD binding site are critical for FAD binding and for the maintenance of the stable and active conformation of rat monoamine oxidase A. J. Biochem., 2002; 131: 107-111
75. Ma J., Yoshimura M., Yamashita E., Nakagawa A., Ito A., Tsukihara T.: Structure of rat monoamine oxidase A and its specific recognitions for substrates and inhibitors. J. Mol. Biol., 2004; 338: 103-114
76. Magyar K., PalfiM., Tabi T., Kalasz H., Szende B., Szoko E.: Pharmacological aspects of (-)-deprenyl. Curr. Med. Chem., 2004; 11: 2017-2031
77. Magyar K., Szende B., Lengyel J., Tarczali J., Szatmary I.: The neuroprotective and neuronal rescue effects of (-)-deprenyl. J. Neural. Transm. Suppl., 1998; 52: 109-123
78. Magyar K., Tothfalusi L.: Pharmacokinetic aspects of deprenyl effects. Pol. J. Pharmacol. Pharm., 1984; 36: 373-384
79. Mahmood I.: Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin. Pharmacokinet., 1997; 33: 91-102
80. Maki Y., Inoue T., Izumi T., Muraki I., Ito K., Kitaichi Y., Li X., Koyama T.: Monoamine oxidase inhibitors reduce conditioned fear stress-induced freezing behavior in rats. Eur. J. Pharmacol., 2000; 406: 411-418
81. Malberg J.E., Schechter L.E.: Increasing hippocampal neurogenesis: A novel mechanism for antidepressant drugs. Curr. Pharm. Des., 2005; 11: 145-155
82. Mallinger A.G., Edwards D.J., Himmelhoch J.M., Knopf S., Ehler J.: Pharmacokinetics of tranylcypromine in patients who are depressed: relationship to cardiovascular effects. Clin. Pharmacol. Ther., 1986; 40: 444-450
83. Mallinger A.G., Smith E.: Pharmacokinetics of monoamine oxidase inhibitors. Psychopharmacol. Bull., 1991; 27: 493-502
84. Mandel S., Weinreb O., Amit T., Youdim M.B.: Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res. Brain Res. Rev., 2005; 48: 379-387
85. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., Herkenham M.A.: Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature, 1984; 311: 464-467
86. Mayersohn M., Guentert T.W.: Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin. Pharmacokinet., 1995; 29: 292-332
87. Minamiura N., Yasunobu K.T.: Bovine liver monoamine oxidase. A modified purification procedure and preliminary evidence for two subunits and one FAD. Arch. Biochem. Biophys., 1978; 189: 481-489
88. Mitoma J., Ito A.: Mitochondrial targeting signal of rat liver monoamine oxidase B is located at its carboxy terminus. J. Biochem., 1992; 111: 20-24
89. Nagatsu T.: Progress in monoamine oxidase (MAO) research in relation to genetic engineering. Neurotoxicology, 2004; 25: 11-20
90. Naoi M., Maruyama W.: Future of neuroprotection in Parkinson's disease. Parkinsonism Relat. Disord., 2001; 8: 139-145
91. Naoi M., Maruyama W., Akao Y., Yi H.: Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines. J. Neural. Transm., 2002; 109: 607-621
92. Naoi M., Maruyama W., Takahashi T., Akao Y., Nakagawa Y.: Involvement of endogenous N-methyl(R)salsolinol in Parkinson's disease: induction of apoptosis and protection by (-)deprenyl. J. Neural. Transm. Suppl., 2000; 58: 111-121
93. Oreland L., Ekblom J., Garpenstrand H., Hallman J.: Biological markers, with special regard to platelet monoamine oxidase (trbc-MAO), for personality and personality disorders. Adv. Pharmacol., 1998; 42: 301-304
94. Paterson I.A., Tatton W.G.: Antiapoptotic actions of monoamine oxidase B inhibitors. Adv. Pharmacol., 1998; 42: 312-315
95. Qin F., Shite J., Mao W., Liang C.S.: Selegiline attenuates cardiac oxidative stress and apoptosis in heart failure: association with improvement of cardiac function. Eur. J. Pharmacol., 2003; 461: 149-158
96. Ramsay R.R.: Kinetic mechanism of monoamine oxidase A. Biochemistry, 1991; 30: 4624-4629
97. Rascol O.: Monoamine oxidase inhibitors-is it time to up the TEMPO? Lancet Neurol., 2003; 2: 142-143
98. Rascol O., Brooks D.J., Melamed E., Oertel W., Poewe W., Stocchi F., Tolosa E., LARGO study group.: Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial. Lancet, 2005; 365: 947-954
99. Rebrin I., Geha R.M., Chen K., Shih J.C.: Effects of carboxyl-terminal truncations on the activity and solubility of human monoamine oxidase B. J. Biol. Chem., 2001; 276: 29499-29506
100. Reynolds G.P., Riederer P., Sandler M., Jellinger K., Seemann D.: Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. J. Neural. Transm., 1978; 43: 271-277
101. Riederer P., Danielczyk W., Grunblatt E.: Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology, 2004; 25: 271-277
102. Riederer P., Lachenmayer L., Laux G.: Clinical applications of MAOinhibitors. Curr. Med. Chem., 2004; 11: 2033-2043
103. Riederer P., Youdim M.B.: Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with ldeprenyl. J. Neurochem., 1986; 46: 1359-1365
104. Riederer P., Youdim M.B., Birkmayer W., Jellinger K.: Monoamine oxidase activity during deprenil therapy: human brain post-mortem studies. Adv. Biochem. Psychopharmacol., 1978; 19: 377-382
105. Riley L.A., Denney R.M.: Problems with the measurement of monoamine oxidase A protein concentration in mitochondrial preparations. Revised molecular activities and implications for estimating ratios of MAO A:MAO B molecules from radiochemical assay data. Biochem. Pharmacol., 1991; 42: 1953-1959
106. Robinson D.S., Cooper T.B., Jindal S.P., Corcella J., Lutz T.: Metabolism and pharmacokinetics of phenelzine: lack of evidence for acetylation pathway in humans. J. Clin. Psychopharmacol., 1985; 5: 333-337
107. Rodriguez M.J., Saura J., Billett E.E., Finch C.C., Mahy N.: Cellular localization of monoamine oxidase A and B in human tissues outside of the central nervous system. Cell Tissue. Res., 2001; 304: 215-220
108. Rodriguez M.J., Saura J., Finch C.C., Mahy N., Billett E.E.: Localization of monoamine oxidase A and B in human pancreas, thyroid, and adrenal glands. J. Histochem. Cytochem., 2000; 48: 147-151
109. Roth J.A., Eddy B.J.: Kinetic properties of membrane-bound and Triton X-100-solubilized human brain monoamine oxidase. Arch. Biochem. Biophys., 1980; 205: 260-266
110. Rybakowski J., Rzewuska M., Czlonkowski A.: Moklobemid-atypowy inhibitor monoaminooksydazy (RIMA). Alfa Medica Press, Bielsko-Biala 2005
111. Sano M., Ernesto C., Klauber M.R., Schafer K., Woodbury P., Thomas R., Grundman M, Growdon J, Thal L.J.: Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer's Disease Cooperative Study. Alzheimer Dis. Assoc. Disord., 1996; 10: 132-140
112. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., Schneider L.S., Thal L.J.: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med., 1997; 336: 1216-1222
113. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., Belzung C., Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science, 2003; 301: 805-809
114. Saura J., Nadal E., van den Berg B., Vila M., Bombi J.A., Mahy N.: Localization of monoamine oxidases in human peripheral tissues. Life Sci., 1996; 59: 1341-1349
115. Schnaitman C., Erwin V.G., Greenawalt J.W.: The submitochondrial localization of monoamine oxidase. An enzymatic marker for the outer membrane of rat liver mitochondria. J. Cell. Biol., 1967; 32: 719-735
116. Schneider L.S., Pollock V.E., Zemansky M.F., Gleason R.P., Palmer R., Sloane R.B.: A pilot study of low-dose L-deprenyl in Alzheimer's disease. J. Geriatr. Psychiatry. Neurol., 1991; 4: 143-148
117. Shih J.C.: Cloning, after cloning, knock-out mice, and physiological functions of MAO A and B. Neurotoxicology, 2004; 25: 21-30
118. Shih J.C., Chen K., Ridd M.J.: Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci., 1999; 22: 197-217
119. Shih J.C., Chen K., Ridd M.J.: Role of MAO A and B in neurotransmitter metabolism and behavior. Pol. J. Pharmacol., 1999; 51: 25-29
120. Shih J.C., Chen K., Ridd M.J., Seif I.: Ginkgo biloba abolishes aggression in mice lacking MAO A. Antioxid. Redox. Signal., 2000; 2: 467-471
121. Shih J.C., Thompson R.F.: Monoamine oxidase in neuropsychiatry and behavior. Am. J. Hum. Genet., 1999; 65: 593-598
122. Shulman K.I., Walker S.E., MacKenzie S., Knowles S.: Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J. Clin. Psychopharmacol., 1989; 9: 397-402
123. Sonsalla P.K., Golbe L.I.: Deprenyl as prophylaxis against Parkinson's disease? Clin. Neuropharmacol., 1988; 11: 500-511
124. Takahata K., Shimazu S., Katsuki H., Yoneda F., Akaike A.: Effects of selegiline on antioxidant systems in the nigrostriatum in rat. J. Neural. Transm. 2006; 113: 151-158
125. Tariot P.N., Cohen R.M., Sunderland T., Newhouse P.A., Yount D., Mellow A.M., Weingartner H., Mueller E.A., Murphy D.L.: L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch. Gen. Psychiatry. 1987; 44: 427-433
126. Tatton W.G., Chalmers-Redman R.M., Elstner M., Leesch W., Jagodzinski F.B., Stupak D.P., Sugrue M.M., Tatton N.A.: Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling. J. Neural. Transm. Suppl., 2000; 60: 77-100
127. Tatton W.G., Greenwood C.E.: Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism. J. Neurosci. Res., 1991; 30: 666-672
128. Tatton W.G., Ju W.Y., Holland D.P., Tai C., Kwan M.: (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J. Neurochem., 1994; 63: 1572-1575
129. Tatton W.G., Wadia J.S., Ju W.Y., Chalmers-Redman R.M., Tatton N.A.: (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J. Neural. Transm. Suppl., 1996; 48: 45-59
130. ThyagaRajan S., Madden K.S., Stevens S.Y., Felten D.L.: Anti-tumor effect of L-deprenyl is associated with enhanced central and peripheral neurotransmission and immune reactivity in rats with carcinogeninduced mammary tumors. J. Neuroimmunol., 2000; 109: 95-104
131. Toronyi E., Hamar J., Magyar K., Szende B.: Antiapoptotic effect of (-)-deprenyl in rat kidney after ischemia-reperfusion. Med. Sci. Monit., 2002; 8(2): BR65-BR68
132. Vetulani J., Nalepa I.: Antidepressants: past, present and future. Eur. J. Pharmacol., 2000; 405: 351-363
133. Vindis C., Seguelas M.H., Lanier S., Parini A., Cambon C.: Dopamine induces ERK activation in renal epithelial cells through H2O2 produced by monoamine oxidase. Kidney Int., 2001; 59: 76-86
134. Von Strauss E., Viitanen M., De Ronchi D., Winblad B., Fratiglioni L.: Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. Arch. Neurol., 1999; 56: 587-592
135. Wecker L., James S., Copeland N., Pacheco M.A.: Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol. Psychiatry, 2003; 54: 1099-1104
136. Wilcock G.K., Birks J., Whitehead A., Evans S.J.: The effect of selegiline in the treatment of people with Alzheimer's disease: A meta-analysis of published trials. Int. J. Geriatr. Psychiatry, 2002; 17: 175-183
137. Yamada M., Yasuhara H.: Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology, 2004; 25: 215-221
138. Yi H., Maruyama W., Akao Y., Takahashi T., Iwasa K., Youdim M.B., Naoi M.: N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J. Neural. Transm., 2006; 113: 21-32
139. Youdim M.B., Bakhle Y.S.: Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br. J. Pharmacol., 2006; 147 Suppl 1: S287-S296
140. Youdim M.B., Bar Am O., Yogev-Falach M., Weinreb O., Maruyama W., Naoi M., Amit T.: Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res., 2005; 79: 172-179
141. Youdim M.B., Buccafusco J.J.: Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci., 2005; 26: 27-35
142. Youdim M.B., Edmondson D., Tipton K.F.: The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci., 2006; 7: 295-309
143. Youdim M.B., Gross A., Finberg J.P.: Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol., 2001; 132: 500-506
144. Youdim M.B., Weinstock M.: Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology, 2004; 25: 243-250
145. Zeller E.A.: Uber den enzymatischen abbau von histamin und diaminen. Helv. Chim. Acta, 1938; 21: 881-890
146. Zeller E.A., Sarkar S.: Amine oxidases. XIX. Inhibition of monoamine oxidase by phenylcyclopropylamines and iproniazid. J. Biol. Chem., 1962; 237: 2333-2336
147. Zhou G., Miura Y., Shoji H., Yamada S., Matsuishi T.: Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 2001; 70: 229-231